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Cardiovascular, Pulmonary and Renal Pathology
The Involvement of the Apoptosis-Modulating
Proteins ERK 1/2, Bcl-xL and Bax in the Resolution
of Acute Inflammation in Vivo
Deborah A. Sawatzky,*† Derek A. Willoughby,*
Paul R. Colville-Nash,* and Adriano G. Rossi†*
From the Department of Experimental Pathology,*
St. Bartholomew’s, and the Royal London Medical School,
London; and the Medical Research Council Centre for
Inflammation Research,† The Queen’s Medical Research Institute,
University of Edinburgh Medical School, Edinburgh, United
Kingdom
Inflammatory cell recruitment, activation, and apo-
ptosis are highly regulated processes involving
several checkpoints controlling the resolution of in-
flammation. We investigated the role of the mitogen-
activated protein kinase (MAPK) signaling pathway
(ie, ERK1/2) and apoptosis-regulating Bcl-2 family
members (ie, Bcl-xL and Bax) in the resolution of a rat
carrageenan-induced pleurisy model. The specific
ERK1/2 inhibitor PD98059 enhanced the resolution of
inflammation, whereas the MEK1/2 inhibitor U0126
had no effect and the flavonoid apigenin, a nonspe-
cific inhibitor of ERK1/2 and COX-2, augmented
inflammation. Specifically, PD98059 significantly
decreased the total number of macrophages and neu-
trophils in the pleural cavity, mainly by increasing
the rate of neutrophil apoptosis, as measured by An-
nexin V labeling and morphological analysis. Con-
versely, a specific inhibitor of proapoptotic Bax (V5)
increased inflammation, indicating that by prevent-
ing apoptosis in vivo , resolution of inflammation is
delayed. This was associated with a decrease in neu-
trophil apoptosis and an increase in macrophage and
neutrophil numbers perpetuating the inflammatory
response. In conclusion, this study shows that
ERK1/2, Bax, and Bcl-xL play important functional
roles in the resolution phase of the acute inflamma-
tory response in vivo by influencing apoptosis. Im-
portantly, these data may provide novel therapeutic
targets for the treatment of inflammatory diseases.
(Am J Pathol 2006, 168:33–41; DOI: 10.2353/ajpath.2006.
050058)
The inflammatory response is a highly regulated process
in which the balance between cell survival and apoptosis
is orchestrated to ultimately drive and resolve inflamma-
tion. In addition, inflammation is controlled by a series of
checkpoints, in which an array of endogenous mediators
act to either elicit and/or to suppress the inflammatory
response, depending on chronology and circumstance.1
Classically, the onset of acute inflammation is character-
ized by the recruitment of neutrophils and eosinophils
from the bone marrow to the local site of inflammation,
regulated by several chemokines and cell adhesion mol-
ecules.2 Here, they are activated by various cytokines
[for example, tumor necrosis factor-, interleukin (IL)-1,
and IL-8], growth factors (GM-CSF), and several other
endogenous mediators (for example, PAF and LTB4).
Resultant degranulation of cytotoxic granules and gener-
ation of toxic oxygen radicals contribute to surrounding
tissue damage. At the peak of the inflammatory response,
with regard to leukocyte recruitment, there is an influx of
monocytes that differentiate into macrophages in situ. It is
thought that these professional phagocytes clear apopto-
tic cells and contribute to resolution by generation of
anti-inflammatory cytokines, such as transforming growth
factor (TGF)-1 and IL-10. On the contrary, phagocytosis
of necrotic cells leads to the generation of proinflamma-
tory signals that fuels persistent inflammation and tissue
damage.3 It is therefore thought that the promotion of
apoptosis of inflammatory cells, hence efficient clearance
by phagocytes, would be a beneficial therapeutic strat-
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egy for inflammatory diseases such as asthma, rheuma-
toid arthritis, and inflammatory bowel disease.
Recently, we have shown the cellular profile of apopto-
sis in an acute pleurisy model of inflammation in vivo.4
One of the key events that initiate the resolution of inflam-
mation (24 to 36 hours) is the induction of neutrophil
apoptosis, which allows for safe clearance by phago-
cytes, such as macrophages. During resolution the ma-
jority of macrophages migrate to the local lymph node,5
however we have shown that some macrophages un-
dergo apoptosis in situ at 72 hours, when inflammation
has almost fully resolved. The signaling molecules and
mechanisms that govern inflammatory cell survival and
apoptosis have not yet been fully elucidated and more
importantly, whether modulating these molecules can
prevent or promote the resolution of the inflammatory
response in an in vivo scenario has not been evaluated.
There are numerous signal transduction molecules that
play a role in determining the fate of the cell, which are
triggered by extracellular signals before committing to
caspase-dependent or -independent cell death.6 The
Bcl-2 and mitogen-activated protein kinase (MAPK) path-
ways have been well characterized in terms of cell apo-
ptosis and cell survival regulation in vitro, however their
effects on the resolution of inflammation in vivo is still
unclear. Bax and Bcl-xL, proapoptotic and anti-apoptotic
Bcl-2 family members, respectively, play key roles in the
regulation of apoptosis.7 For example, it has been shown
that eosinophils isolated from children with acute asthma
had an increased expression of Bcl-2, which was in-
versely correlated with the expiratory flow rate.8 In addi-
tion, Bax expression is attenuated and Bcl-xL expression
is increased in T cells isolated from the lamina propria
from patients with Crohn’s disease.9 This shows that in-
flammatory cell survival, by means of prosurvival and
anti-apoptotic signaling mechanisms are important in the
pathogenesis of inflammatory diseases. It has yet to be
determined if modifying proteins from the Bcl-2 family
can modulate inflammation per se.
The three main cascades by which MAPK homologues
are released via MAPK kinase (MEK 1-7) are the extra-
cellular signal-regulated kinase (ERK) (p42, p44, MAPK),
c-Jun amino-terminal kinases (JNKs), and p38 MAPK
pathways.10 The endogenous homologues of MAPK all
play roles in cell differentiation, apoptosis, stress re-
sponses, and inflammation.11 In inflammatory diseases,
such as asthma and rheumatoid arthritis, MAPK expres-
sion is increased.12 ERK1/2 can be activated for a rela-
tively prolonged period of time under certain inflamma-
tory conditions, in which it has been shown that
macrophage inhibitory factor (MIF) induces ERK1/2 via
cPLA2-induced arachidonic acid generation for a period
of 24 hours in culture, which may partially account for the
mechanism of ERK-induced cellular proliferation.13 In ad-
dition, macrophage ingestion of apoptotic cells liberate
mediators3 that can influence inflammatory cell survival
via MAPK pathways.
Studies have also shown that inhibitors of p38 MAPK,
such as RWJ-67657, SB203580, and SB242235, are ef-
fective anti-inflammatory agents in suppressing cytokine
release in human clinical trials ex vivo14 and also in the
rat adjuvant-induced arthritis and in murine collagen-
induced arthritis models in vivo.15,16 Inhibitors of ERK 1/2,
such as PD98059, have also been shown to inhibit eo-
sinophilic proinflammatory cytokine release, differentia-
tion, and degranulation in vitro.17 Interestingly, flavonoids,
such as apigenin, also possess anti-inflammatory prop-
erties in vitro through antioxidant mechanisms;18 inhibi-
tion of cell adhesion molecule expression, such as ICAM-
1,19,20 and by attenuating the release of inflammatory
mediators such as IL-1-induced PGE2 via the inhibition
of MAPK.21 In vivo studies have shown that flavonoids
attenuate the onset of acute inflammation in murine mod-
els of carrageenan-induced paw edema and peritonitis,
which is attributable to PGE2 and LTB4 inhibition.
22 Al-
though flavonoids, such as apigenin, are effective at
preventing the onset of inflammation, it is unclear whether
flavonoids exert anti-inflammatory effects once inflamma-
tion is established and whether they can promote the
resolution of inflammation. We therefore hypothesize that
inhibiting prosurvival factors, such as ERK 1/2 and Bcl-xL,
or inducing proapoptotic proteins, such as Bax, may lead
to the safe clearance of inflammatory cells and aid the
resolution of acute inflammation. In this study, we exam-
ined the expression profile of apoptosis-modulating pro-
teins during the inflammatory response and investigated
whether inhibition of these specific proteins can result
in the advancement or delay of the resolution of
inflammation.
Materials and Methods
All materials were purchased from Sigma-Aldrich Ltd.
(Poole, UK) unless otherwise stated. Bax-inhibiting pep-
tide (V5), PD98059, and U0126 were purchased from
Calbiochem (Nottingham, UK). Viscarin (-carrageenan)
was a kind gift from Marine Colloids Inc. (Philadelphia,
PA). Antibodies to Bax, Bcl-xL, and pERK 1/2 were pur-
chased from Autogen Bioclear (Wiltshire, UK).
Carrageenan-Induced Pleurisy
Male Lewis rats (250 to 300 g) (Tuck and Sons, Battle-
bridge, UK) were housed in the University of Edinburgh
animal facilities in accordance with local guidelines. An-
imals were fed on a normal diet with tap water ad libitum
and were housed in a 12-hour light/dark cycle, at 20 to
21°C and with 50% humidity levels. The first described
model of carrageenan-induced inflammation was by Win-
ter and co-workers23 in the paw edema model. Since
then, the carrageenan-induced pleurisy model has been
further developed and widely used as an acute resolving
model of inflammation.24 Briefly, the animals were anes-
thetized with halothane, a small incision was made to
expose the musculature and 0.15 ml of 1% viscarin (-
carrageenan) was injected intrapleurally with a blunted
21-gauge needle. Animals were killed by a rising con-
centration of CO2 at various time points after carra-
geenan administration, from the onset (6 hours), the peak
(24 hours), and during the resolution of inflammation (36,
48, and 72 hours). Pleural cavities were washed with 1 ml
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of 3.15% (w/v) sodium citrate in physiological saline.
Total inflammatory cell pellets were harvested for analysis
by Western blotting.
In Vivo Treatment with 2-Amino-3-
Methoxyflavone (PD98059), 1,4-Diamino-2,3-
Dicyano-1,4-Bis(O-Aminophenylmercapto)
Butadiene (U0126), or Bax-Inhibiting Peptide V5
Rats were treated with 0.15 ml of saline control, 0.15 ml of
0.1% or 0.8% dimethyl sulfoxide vehicle control, or with
300 mol/L PD98059, 300 mol/L U0126, or 200 mol/L
Bax-inhibiting peptide (V5) intrapleurally 36 hours after
injection with 1% carrageenan. Animals were culled by a
rising concentration of CO2 48 hours after injection with
carrageenan (12 hours after drug treatment). Pleural cav-
ities were washed with 1 ml of 3.15% (w/v) sodium citrate
in physiological saline. Edema formation was measured
by weighing the total pleural exudates, and total cell
counts were measured with a Coulter Counter (model
DN; Coulter Electronics, Luton, UK). An aliquot of 1 106
inflammatory cells were washed in PBS three times and
labeled with fluorescein isothiocyanate-conjugated An-
nexin V according to the manufacturer’s instructions. To-
tal cell apoptosis was measured by Annexin V labeling
according to the manufacturer’s instructions and ana-
lyzed by the BD FacsCalibur (Becton-Dickinson, Moun-
tain View, CA). Lymphocyte, polymorphonuclear leuko-
cyte (PMNs), and monocyte/macrophage total numbers
were counted by light microscopy from hematoxylin and
eosin (H&E)-stained cytospin preparations and con-
firmed by flow cytometry as described.4 Total neutrophil
apoptosis was also measured by morphological analysis
by light microscopy from H&E-stained cytospin prepara-
tions of pleural inflammatory cells with data presented as
the percentage of apoptotic neutrophils from the total
number of neutrophils present.
Western Blot Analysis
Inflammatory cell pellets were lysed in the presence of
protease inhibitory buffer containing 1 mol/L phenyl-
methyl sulfonyl fluoride, 1.5 mol/L pepstatin A, and 0.2
mol/L leupeptin. Protein concentrations were deter-
mined by the Bradford assay, and equal protein loading
was confirmed by -actin blotting (data not shown). Sam-
ples were boiled for 5 minutes with equal volumes of
Laemmli gel loading buffer (5 mmol/L Tris, 10% sodium
dodecyl sulfate, 10% glycerol, 10% -mercaptoethanol,
and 2 mg/ml bromophenol blue). Total protein equiva-
lents of 10 g for each sample were run on 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and
were transferred to nitrocellulose paper (Amersham, UK)
using the Bio-Rad minigel system (Bio-Rad, Hemel
Hempstead, UK). Nonspecific antibody binding was
blocked with 5% dried milk protein, and blots were incu-
bated with either polyclonal goat or rabbit antibodies
against pERK 1/2 (1:1000 dilution), Bax (1:500 dilution),
or Bcl-xL (1:1000 dilution).
Statistics
All experiments were performed with six to eight rats per
group, with experiments repeated to verify the original
findings. Statistical analysis was performed by a one-way
analysis of variance with Bonferroni multiple comparison
post hoc test with a 95% confidence interval or by a
Student’s t-test as appropriate. Data are expressed as
mean  SEM.
Results
Expression Profiles of Signaling Molecules
Involved in Apoptosis
Inflammatory cells from the onset of inflammation in a rat
carrageenan-induced pleurisy model (6 to 36 hours after
carrageenan) expressed the prosurvival molecules
pERK1/2 and Bcl-xL with very low levels of Bax expres-
sion found (Figure 1). Conversely during the resolution of
inflammation (48 hours after carrageenan), Bax protein
expression was increased with negligible levels of
pERK1/2 and Bcl-xL expression.
Modulation of Proapoptotic or Prosurvival
Proteins Can Enhance or Prevent the Resolution
of Inflammation in Vivo
Functional studies were conducted to assess whether
inhibition of the prosurvival ERK1/2 could alter the reso-
lution of inflammation in the carrageenan-induced pleu-
risy model. Once inflammation was established in the
pleural cavity 36 hours after carrageenan, the flavonoid
apigenin, a nonspecific ERK1/2 inhibitor, was given lo-
cally by intrapleural injection. Although apigenin did not
affect edema, it was found to exacerbate inflammation
with an increased total amount of pleural cell numbers of
112.6  106 6.4 cells compared with vehicle-treated
control of 71.7  106 7.3 cells (*P  0.05; Figure 2).
The specific ERK1/2 inhibitor PD98059 augmented the
resolution of inflammation by reducing cell numbers in
Figure 1. Expression of the prosurvival proteins, pERK 1/2 and Bcl-xL, and
the proapoptotic signaling protein, Bax, during the onset and resolving phase
of inflammation. Male Lewis rats were injected intrapleurally with 1% carra-
geenan and inflammatory cells were harvested at various time points during
the onset (6 to 24 hours) and resolving phase of acute inflammation (36 to 72
hours). Equal protein equivalent was determined by Bradford assay and 10
g was loaded for each sample. Protein expression of pERK1/2, Bcl-xL, and
Bax were measured by electrophoresis and Western blotting. Data are rep-
resentative of three separate experiments.
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the pleural cavity to 50  106 5.2  106 cells (n  8;
Figure 3B) compared with vehicle control of 81  106
5.6  106 cells (**P  0.01) when given 36 hours after
carrageenan. PD98059 pretreatment halved the total cell
number of PMNs (*P  0.05) and also monocytes/mac-
rophages (***P  0.001) compared with vehicle-treated
control (Figure 5A). Edema formation decreased with
PD98059 treatment by 30% when compared with saline
control; however, PD98059 treatment was not signifi-
cantly different from vehicle-treated control (Figure 3A).
Inflammatory cell apoptosis, measured by Annexin V
binding and analyzed by flow cytometry, was significantly
enhanced with PD98059 resulting in a 25% increase in
binding when compared with vehicle control (n  8, *P 
0.05; Figure 3C). Specifically, there was as increase of
apoptotic neutrophils with PD98059 pretreatment by
50  6% (n  6, **P  0.01; Figure 5B), which was
approximately double the amount of constitutive apopto-
sis found in the saline and vehicle-treated control groups.
Neutrophil apoptosis was further illustrated with H&E-
stained inflammatory cells (Figure 5C). In contrast, the
MEK1/2 inhibitor U0126 had no effect on the exudate
volume, total cell number, or cell apoptosis levels (Figure
3, D–F).
We have shown that by enhancing apoptosis, via inhi-
bition of ERK1/2, there is a significant attenuation of in-
flammation. On the contrary, it was also important to
assess whether direct inhibition of apoptosis can alter the
resolution of inflammation. A specific inhibitor of Bax
prevented the safe resolution of inflammation with an
increase in numbers of inflammatory cells to 121.9 
106 16.7  106 cells (n  8; Figure 4) compared with
saline alone to 78.3  106 9.5  106 cells (n  8) when
administered locally at the peak of inflammation. Specif-
ically, the total amount of PMNs and monocytes/macro-
phages increased by 42% and 33%, respectively, com-
pared with saline control (*P  0.05, ***P  0.001; Figure
5A). There was also a significant decrease (35%, *P 
0.05, n  8) in Annexin V binding compared with control,
which further supports the hypothesis that the aug-
mented inflammation was due to the prevention of apo-
ptosis, which would normally occur during the resolution
phase of inflammation. In particular, Bax inhibition
caused a decrease in the number of apoptotic neutro-
phils, in which only 7.2% of neutrophils were apoptotic
within the total number of neutrophils present (Figure 5, B
and C; *P  0.05). Interestingly, although TGF-1 was
prevalent during resolution (36 hours after carrageenan),
Figure 2. Apigenin, a nonspecific inhibitor of ERK1/2 and COX-2, inhibited
the resolution of inflammation. Male Lewis rats were injected intrapleurally
with 1% carrageenan and after 36 hours were treated intrapleurally with
saline, vehicle-treated control, or 30 mol/L apigenin. Twelve hours later
edema formation (A) and total inflammatory cell numbers (B) were mea-
sured (48 hours after the onset of the carrageenan-induced pleurisy). Data
are the mean of six animals per group  SEM, *P  0.05.
Figure 3. The specific ERK 1/2 inhibitor, PD98059, enhanced the resolution
of inflammation, whereas the MEK inhibitor U0126 had no effect. Male Lewis
rats were injected intrapleurally with 1% carrageenan and after 36 hours were
treated intrapleurally with saline, vehicle-treated control, 300 mol/L
PD98059, or 300 mol/L U0126. Twelve hours later edema formation (A and
D) and total inflammatory cell numbers (B and E) were measured (48 hours
after the onset of the carrageenan-induced pleurisy). Levels of apoptosis (C
and F) were measured by Annexin V binding and analyzed by flow cytom-
etry. Data are the mean of eight animals per group  SEM, *P  0.05 and
**P  0.01.
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there was no significant difference in TGF-1 or IL-10
levels in any of the treatment groups (data not shown).
Discussion
The balance between prosurvival and proapoptotic sig-
nals is a highly regulated process involving many check-
points that regulate cell survival and death.1,25 Several
proinflammatory mediators, such as fMLP,26 tumor ne-
crosis factor-,27 GM-CSF,28 PAF,29 LTB4,
30 influence
apoptosis of inflammatory cells,31 and trigger MAPK
pathways. This study has shown that during the initiation
of acute inflammation, expression of prosurvival mole-
cules, such as ERK1/2 and Bcl-xL, are increased. Fur-
thermore, we also show that the expression of these
survival factors is down-regulated during the resolution
phase. Conversely, the proapoptotic signaling molecule
Bax is up-regulated when the inflammation is resolving
with low expression levels found during the onset of
inflammation. The functional role of cell signaling pro-
teins, such as Bax, MEK1/2, and ERK1/2, in inflammation
in vivo was previously undetermined.
This study demonstrates for the first time that apopto-
sis-modulating pharmacological inhibitors can promote
or delay the resolution of acute inflammation. Importantly,
the specific ERK1/2 inhibitor, PD98059, accelerates res-
olution of inflammation even after inflammation was es-
tablished. It is difficult to predict in patients when inflam-
mation will occur, even in chronic inflammatory diseases,
and therefore, treatment during flare-ups is more benefi-
cial than a prolonged prophylactic drug treatment re-
gime. Furthermore, this is an advantageous therapeutic
strategy that will allow neutrophil infiltration to combat
invading pathogens but will limit persistent inflammation
and excessive tissue damage. Premature neutrophil
apoptosis during infection is likely to be detrimental to
host defense and lead to bacterial infection and sepsis.
This is a known complication in cystic fibrosis patients in
which the Pseudomonas aeruginosa-derived exotoxin
pyocyanin induces neutrophil apoptosis, which allows
inflammatory cells and bacteria to persist contributing to
pulmonary damage and patient mortality.32
The effects of endogenous or exogenous mediators
depend on the kinetics of the synthesis or release or the
timing of the administration of the inflammatory process.
Studies have shown that in the carrageenan-induced
paw edema model, apigenin had an anti-inflammatory
effect when given at the onset of inflammation.33 This
effect would be consistent with the suppression of COX-2
inhibiting inflammation when given prophylactically. In
the present study, the nonselective ERK1/2 inhibitor api-
genin exacerbated inflammation, which in part is likely
due to an inhibition of COX-2 because it has been shown
that selective COX-2 inhibition by NS-398 and traditional
NSAIDs, when given during the peak of inflammation,
causes a prolonged inflammation.34 This is likely due to
inhibition of the anti-inflammatory cyclopentenone pros-
taglandins, 15deoxy,12,14 PGJ2, and PGD2, which di-
rectly promote the apoptosis of neutrophils and macro-
phages in situ.4 Further evidence of the anti-inflammatory
role of COX-2 was also shown by Wallace and co-work-
ers35 in which inflammation failed to resolve in COX-2
knockout mice in a model of carrageenan-induced paw
inflammation.
Here, we show that pretreatment with the specific
ERK1/2 inhibitor PD98059 enhanced the resolution of
acute inflammation, with attenuated total cell numbers of
monocytes/macrophages and PMNs in the pleural cavity.
This correlated with an increase in the number of free
apoptotic neutrophils found after pretreatment with
PD98059. The increased amount of free apoptotic cells
was probably not due to a defective phagocytosis mech-
anism because previous studies have shown that
PD98059 does not affect phagocytosis in many different
in vitro assays.36–38 In the present study, we also quali-
tatively show that the macrophage can still ingest apo-
ptotic cells, as indicated in Figure 5C. The ability to
visualize the free apoptotic neutrophils may be a result of
a pronounced increase in apoptosis levels and a re-
duced number of the professional phagocytes (macro-
phages) in the pleural cavity. The persistence of free
apoptotic cells has recently been suggested to be anti-
inflammatory dependent on the environment that the
macrophage is exposed to.39,40 Interestingly, autologous
administration of apoptotic cells has been clinically
proven to help prevent heart, lung, and renal allograft
transplant rejection.41–44 This is thought to occur as a
result of tolerogenic changes of immature dendritic cells
after the engulfment of the apoptotic cells, which then
stimulates inhibitory T-regulatory cells that suppress im-
mune rejection.45 This clearly shows that the administra-
tion of apoptotic cells and their safe engulfment in hu-
Figure 4. The Bax-inhibiting peptide V5 prevented the safe resolution of
inflammation. Male Lewis rats were injected intrapleurally with 1% carra-
geenan and after 36 hours were treated intrapleurally with saline or 200
mol/L Bax-inhibiting peptide V5. Twelve hours later edema formation (A)
and total inflammatory cell numbers (B) were measured (48 hours after the
onset of the carrageenan-induced pleurisy). Levels of apoptosis (C) were
measured by Annexin V binding and analyzed by flow cytometry. Data are
the mean of 10 animals per group  SEM, *P  0.05, **P  0.01.
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mans has a role in the adaptive and the innate immune
system by stimulating tolerance and promoting the reso-
lution of inflammation. In this study, there is an overall
diminished inflammatory response with PD98059 treat-
ment in which increased apoptosis of neutrophils leads to
an enhanced resolution of inflammation.
The accelerated resolution of inflammation was a spe-
cific effect for PD98059 because the MEK1/2 inhibitor
Figure 5. The specific ERK1/2 inhibitor PD98059 augments neutrophil apoptosis, whereas the Bax-inhibiting peptide promoted neutrophil survival. Male Lewis
rats were injected intrapleurally with 1% carrageenan and after 36 hours were treated intrapleurally with saline, vehicle-treated control, 300 mol/L PD98059, or
200 mol/L Bax-inhibiting peptide V5. A: Twelve hours later, the total number of lymphocytes (open bars), neutrophils (filled bars), and monocytes/
macrophages (dotted bars) was counted by flow cytometric analysis and differential cell counts by light microscopy. B: Neutrophil apoptosis was measured by
morphological analysis by light microscopy after H&E staining with data presented as the percentage of apoptotic neutrophils from the total number of neutrophils
present. Examples of this in a typical field are illustrated showing the distinct nuclei of apoptotic neutrophils (arrows), phagocytosed apoptotic neutrophils
(arrowhead), and viable neutrophils (asterisk) after vehicle, PD98059, or Bax inhibitor (V5) pretreatment. Original magnifications, 60.
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U0126 had no anti-inflammatory effect in terms of inflam-
matory cell numbers and apoptosis levels in vivo. U0126
has been shown to be specific for MEK1/2 and is non-
competitive with ERK and ATP.46 This indicates that
MEK1/2 may be disassociated from the ERK1/2 signaling
pathway, which may provide a novel pathway for cell
survival in inflammation. Alternatively U0126 could be
ineffective in this model. Recently however, administra-
tion of U0126 at the onset of inflammation in a murine
model of ovalbumin-induced asthma has been shown to
be effective in reducing eosinophilia, proinflammatory
cytokine release, and airway hyperresponsiveness.47 In
an in vitro study, there was a suppression of the release of
eotaxin, RANTES, and GM-CSF from human airway
smooth muscle cells with the MEK 1/2 inhibitor U0126;
however, no effect was observed with a range of concen-
trations of the ERK1/2 inhibitor PD98059.48 The authors
argue that PD98059 has poor efficacy, which is different
from the findings proposed here, in which this compound
augmented the resolution of inflammation. The local con-
centrations of the PD98059 and U0126 compounds were
consistent with EC50 values shown in other in vitro
studies.21
The Bax-inhibiting peptide V5 is a cell-permeable pen-
tapeptide that blocks the ku70 binding domain and pre-
vents Bax conformational change and mitochondrial
translocation.49 This peptide has been shown to inhibit
staurosporine-, UV-, and anti-cancer drug-induced apo-
ptosis in vitro.50 In the present study, inhibition of Bax
during the resolving phase of acute inflammation exac-
erbated the inflammatory response in vivo. Specifically,
total pleural cell numbers of monocytes/macrophages
and PMNs were increased, with a corresponding de-
crease in the amount of neutrophil apoptosis, after pre-
treatment with the specific Bax inhibitor. Other studies by
Maiuri and co-workers51 show that induction of Bax via
inhibition of nuclear factor-B in a carrageenan sponge
model of chronic inflammation is associated with the
apoptosis of neutrophils.
A decrease in total cell apoptosis, which could be
attributed mainly to neutrophil apoptosis, was observed
with the Bax peptide inhibitor. In contrast, an increase in
neutrophil apoptosis contributed to an enhanced resolu-
tion with the ERK1/2 inhibitor PD98059. The percent total
apoptosis of pleural cells in control and drug-treated
animals were relatively small. This likely reflects the diffi-
culty in visualizing and measuring apoptosis due to effi-
cient clearance by phagocytosis. There is also a very
limited window of opportunity to visualize free apoptotic
cells in vivo, in which the estimated duration of detectable
apoptosis due to rapid recognition and efficient engulf-
ment by phagocytes is only 1 to 2 hours.52,53 However,
even the levels of apoptosis that we have observed may
have significant biological effects because studies have
shown that small changes in apoptosis levels can dras-
tically affect the overall total cell number. For example, in
the rat liver an increase of 2% apoptosis by histological
examination results in an overall 25% reduction in cell
number.54 Furthermore, our previous work shows that an
approximate 3% induction of apoptosis contributes to an
80% reduction in the number of neutrophils in the carra-
geenan-induced pleurisy model of inflammation in vivo.4
Results of previous studies suggest that phagocytosis
of apoptotic cells results in release of anti-inflammatory
cytokines, such as TGF-1
3 and IL-10.55 Furthermore, the
released TGF-1 is capable of inhibiting the release of
proinflammatory cytokines modulated via p38 MAPK
whereby the inhibitor, SB 203580, prevented TGF-1-
mediated inhibition of lipopolysaccharide-induced tumor
necrosis factor- and MIP-2 release.56 In this study, how-
ever, there was no significant difference in TGF-1 or
IL-10 levels found using the Bax inhibitor-, PD98059-, or
the U0126-treated groups (data not shown). However,
silent phagocytosis of early apoptotic cells can occur
without affecting cytokine levels.57 The levels of proin-
flammatory cytokines, such as tumor necrosis factor-
and IL-1, are insignificant during the resolution of inflam-
mation; therefore, we were unable to establish whether
inducing or preventing apoptosis in vivo affects these
cytokines in particular.
Although we have clearly shown in this study that
manipulation of pathways that influence apoptosis
(namely ERK1/2 and Bax) can accelerate the resolution
of an acute model of inflammation, the question remains
whether our observations could be extended to a more
chronic inflammatory scenario. Many of the pathways that
we have investigated here can affect cell recruitment and
activation, in addition to influencing cell survival and
apoptosis. Furthermore, it is now becoming clear that
MAPK signaling pathways and proteins involved in the
regulation of apoptosis are dysregulated in a number of
pathological inflammatory conditions, such as asthma.12
The challenge now is to investigate whether such manip-
ulation of these pathways influences the resolution phase
of inflammation in animal models of chronic inflammation
or, more importantly, whether chronic inflammatory dis-
eases in humans can be beneficially influenced. The
clinical trials currently underway with compounds that
directly influence apoptosis (eg, the caspase inhibitors58)
Figure 6. A schematic diagram showing the balance between prosurvival
and proapoptotic signaling molecules from the onset to the resolution of
acute inflammation. This figure shows that prosurvival proteins such as
ERK1/2 and Bcl-xL predominate during the onset of inflammation, which
when inhibited promotes apoptosis and aids resolution. The expression of
proapoptotic molecules such as Bax are relatively low at this time point.
Conversely, during resolution of inflammation, the balance switches toward
the expression of proapoptotic signaling molecules, Bax, which ultimately
promotes cell death and safe clearance by phagocytosis.
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and compounds that have an indirect effect on cell sur-
vival (eg, JNK, ERK, and p38 kinase inhibitors59) will
identify whether manipulation of apoptosis would be clin-
ically beneficial for chronic inflammatory diseases.
Overall this study shows that direct modulation of
apoptosis through interfering with the signaling of impor-
tant molecules (ERK 1/2, Bcl-xL, Bax) can exacerbate or
attenuate cell infiltrate and edema formation. Thus evi-
dence from in vitro data and from the evidence presented
here suggest that promoting apoptosis and safe clear-
ance of effete cells may be a valuable new therapeutic
target for inflammatory diseases.60 There is also a greater
need to elucidate effective mechanisms of inducing
apoptosis of inflammatory cells in vivo and whether this
affects the outcome of the disease process once inflam-
mation is established. This study emphasizes that there is
an intricate balance of survival and apoptotic signaling
pathways that mediate the kinetics of the acute inflam-
matory response, as illustrated in Figure 6. The enhanced
resolution of inflammation by the inhibition of the prosur-
vival mediators, such as ERK 1/2 with PD98059 may
prove to be an important advancement for the develop-
ment of new treatments of inflammatory diseases.
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